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We investigated the role that erythroviruses (parvovirus B19
and erythrovirus genotypes 2 and 3) play in the lives of
immunosuppressed HIV-infected patients with chronic ane-
mia. We screened the serum samples of 428 patients by spe-
cific ultrasensitive real-time polymerase chain reaction assay.
Sixteen patients had circulating DNA, with no apparent clin-
ical impact. Erythrovirus-associated anemia is an extremely
rare event in HIV-infected patients.
Parvovirus B19 (PVB19), by targeting human erythroid pro-
genitors, is responsible for acute anemia among patients with
hemolytic disorders [1]. For severely immunocompromised
patients, including HIV-infected patients with low CD4 cell
counts, the case reports and case series of chronic anemia due
to high levels of PVB19 replication associated with pure red
cell aplasia have been reported [2–5]. Recently, 2 variants of
PVB19 belonging to erythroviruses in the Parvovividae family
(erythrovirus genotypes 2 and 3, formerly called erythrovirus
variants A6 and V9, respectively) have been described. However,
their pathogenic role has not been established, even among
immunocompromised patients [6, 7].
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Chronic anemia is common among HIV-infected patients
and is a predictor of shorter survival [8]. PVB19 is considered
to be a rare cause of acute or chronic anemia in the HIV-
infected population, despite a high seroprevalence [9]. How-
ever, in the study performed by Naides et al [10] in 1993, many
patients who were intolerant to azidothymidine (AZT) had
PVB19 infection. Recent data revealed that, by using a highly
sensitive PVB19 polymerase chain reaction (PCR) detection
assay, low titers of PVB19 DNA were associated with mild to
severe chronic anemia for a selection of patients who received
a renal transplant [11] and that the newly described erythro-
virus genotype 3 has been detected in 3 HIV-infected patients
with chronic anemia [6]. We aimed to assess the prevalence of
circulating erythrovirus DNA in immunocompromised HIV-
infected patients with chronic anemia.
Methods. HIV-infected patients included in the Swiss HIV
Cohort Study during the period from January 1998 through
April 2008 were screened for erythrovirus DNA by use of a
highly sensitive real-time PCR method. Inclusion criteria were
(1) Agence Nationale de Recherches sur le SIDA et les He´patites
Virales grade 1 (or higher) persistent anemia (with a hemo-
globin level !10.5 g/dL [2 consecutive results with at least 3
months between each sampling]), (2) immunosuppression (CD4
cell count 500 cells/mL) during the episode of anemia, and (3)
availability of at least 1 serum or plasma sample at the time of
the determination of hemoglobin level or between the 2 deter-
minations of hemoglobin level. Patients with ribavirin exposure
at any time time between the 2 determinations of hemoglobin
level were excluded. Patients exposed to myelosuppressive drugs
were not excluded, because they might be associated with eryth-
rovirus reactivation.
DNA was extracted from frozen serum or plasma with the
Qiagen DNA mini kit (Qiagen). PVB19 and erythrovirus ge-
notype 2 or 3 DNA were detected and quantified by an ultra-
sensitive real-time PCR targeting the VP1 gene, a well-con-
served region of the erythrovirus genomes, using an extract
volume corresponding to 10 mL of plasma in duplicate, with
an extra reaction spiked with 1000 copies of PVB19 DNA as
an inhibition control. Two forward primers (B19_2785_F1: 5′-
CTTACACAAGCCTGGGCAAGTTAG-3′; and B19_2785_F2:
5′-CTTACACAAGCCTGGGCGAGTTAG-3′; 50 nM each) and
3 reverse primers (B19_2867_R1: 5′-GGGGCCCAGCTTGTA-
GCTCATT-3′; B19_2867_R2: 5′-GAGGCCCAGCTTGTAGCT-
CATT-3′; and B19_2867_R3: 5′-GAGGCCCAGCTTGTAACT-
CATT-3′; 33 nM each) were used. The analytical sensitivity,
using a 17-base minor-groove binder probe (B19_2817_P FAM-
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Table 1. Baseline Characteristics of Patients With or Without Erythrovirus Replication
Characteristic
Patients with
erythrovirus replication
( )np 16
Patients without
erythrovirus replication
( )np 412 P
Age,a years 43.5 (40–46) 44 (40–50) .422
Male sex 5 (31.3) 160 (38.8) .541
White 12 (75.0) 260 (63.1) .332
European ancestry 13 (81.3) 290 (70.4) .416
Intravenous drug user 8 (50.0) 145 (35.2) .225
Men who have sex with men 3 (18.8) 59 (14.3) .714
CD4 cell count,a cells/mL 191.0 (156.5–322.0) 184.5 (77.0–290.0) .223
Median log10 HIV-1 RNA level,
a copies/mL 4.13 (3.66–11.04) 6.68 (3.66–11.06) .819
Patients without HIV-1 replicationa,b 6 (40.0) 150 (36.7) .793
Tested positive for HBsAg 2 (13.3) 28 (7.3) .313
Tested positive for hepatitis C antibody 7 (43.8) 173 (42.6) .928
Duration of AIDS, years 10.1 (4.1–15.7) 8.2 (3.1–13.6) .332
Diagnosis of AIDSa,b 8 (57.1) 214 (67.1) .563
Received ARTa 11 (68.8) 281 (68.4) .910
Received ART with AZTa 6 (37.5) 133 (32.3) .651
Hemoglobin level,a g/dL 9.6 (9.3–9.9) 9.4 (8.5–10.0) .574
Hemoglobin level !9.5 g/dL 7 (43.8) 206 (50.1) .617
NOTE. Data are no. (%) of patients or median value (interquartile range [IQR]). HBsAg, hepatitis B surface antigen;
ART, antiretroviral therapy; AZT, azidothymidine; IQR, interquartile range.
a During episode of anemia.
b The calculation of the percentages was done after considering missing values.
TACCCGGTACTAACTAT-MBG-DQ; 100 nM), an ABgene
QPCR Rox mix AB-1139b, and a 15-s, 95C, 1-min, 60C cycle
on a taqMan 7900 machine, was close to 1 input copy of viral
DNA (the World Health Organization International Standard
for parvovirus B19 DNA was used for calibration—National
Institute for Biological Standards code 99/800) [12]. In each
run, the linearity of the Ct/input DNA relationship was verified
from 10 to 100,000 copies/reaction using appropriate standards.
From the entire patient population, we compared the char-
acteristics of patients with erythrovirus replication with those
without erythrovirus replication, and from that patient pop-
ulation, we subsequently compared the number of patients with
AZT exposure. We used the x2 test to compare qualitative var-
iables, and we used the Fisher exact test (as appropriate) and
the nonparametric Mann-Whitney test to compare continuous
variables. All statistical tests were 2 sided, and a threshold of
5% was chosen as a cutoff for declaring statistical significance.
We finally went back to the medical files of patients with eryth-
rovirus replication to determine the characteristics of anemia
by collecting additional biological data (eg, the mean corpus-
cular volume, the reticulocyte cell count, the iron and ferritin
serum levels).
Results. There were 428 patients who fulfilled the inclusion
criteria. At study entry, 165 (39%) were male, the median age
was 44 years (interquartile range [IQR], 40–50 years), and 153
(36%) reported intravenous drug use. The median CD4 cell
count was 185 cells/mL (range, 77–290 cells/mL), with 150 pa-
tients having a CD4 cell count of !50 cells/mL. The median
hemoglobin level was 9.4 g/dL (range, 8.5–10.0 g/dL), and 138
patients (32%) were exposed to AZT at the time blood samples
were obtained.
Erythrovirus DNA was detected in 16 patients (4%). The
erythrovirus viral load ranged from 18 to 6820 copies/mL and
was detectable at a very low level (!500 copies/mL) in 13 (81%)
of the 16 patients. No statistically significant differences in char-
acteristics at the time of sampling were noticed after compar-
ison of patients with erythrovirus replication with those without
erythrovirus replication (Table 1). Erythrovirus replication was
not more frequently detected in patients with a CD4 cell count
of !200 cells/mL (9 [56%] vs 7 [44%] of 16 patients with
erythrovirus replication). Of note, the prevalence of intravenous
drug users seemed to be higher among patients with erythro-
virus replication than among patients without erythrovirus rep-
lication (8 [50%] of 16 patients vs 145 [35%] of 412 patients;
). However, both groups of patients had similar me-Pp .225
dian hemoglobin levels (hemoglobin level of 9.6 g/dL [IQR,
9.3–9.9 g/dL] for patients with erythrovirus replication vs 9.4
g/dL [IQR, 8.5–10.0 g/dL] for patients without erythrovirus
replication; ) and a similar prevalence of severe anemiaPp .574
(7 [44%] of 16 patients with erythrovirus replication vs 206
[50%] of 412 patients with erythrovirus replication; ).Pp .617
Circulating erythrovirus DNA was detected in only 6 (4%) of
the 139 patients on AZT, and no statistically significant differ-
ence was noticed between patients with circulating erythrovirus
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DNA and patients without circulating erythrovirus DNA (data
not shown).
Finally, the origin of anemia for the 16 patients with erythro-
virus replication was mainly considered to be carential (6 pa-
tients experienced iron deficiency) or multifactorial (HIV in-
fection with or without AZT therapy, cirrhosis, drug abuse,
chronic renal insufficiency, and/or acute non–Hodgkin lym-
phoma). None of our patients presented with pure red cell
aplasia.
Discussion. We found that PVB19 and erythrovirus ge-
notype 2 or 3 DNA detection was infrequent in the blood
samples of a large cohort of immunocompromised HIV-in-
fected anemic patients, despite using highly sensitive real-time
PCR methods. The typical clinical presentation of PVB19 in-
fection for HIV-infected patients includes transfusion-depen-
dent severe anemia with reticulocytopenia [2–5]. This clinical
form of anemia, which requires multiple infusions of intra-
venous immunoglobulins and the introduction of highly active
antiretroviral therapy to recover, is rarely observed, despite a
high PVB19 seroprevalence in HIV-infected individuals (eg,
81% of HIV-infected individuals vs 57% of individuals in the
general population of Switzerland) [2–5, 8]. Previous studies
that tried to detect circulating PVB19 DNA in the blood sam-
ples of anemic HIV-infected patients were limited, because the
studies (1) included only a small number of patients; (2) were
performed before the year 2000, mainly using qualitative dot
blot PCR (which may have a low sensitivity) or nested PVB19
PCR; and (3) did not detect the newly described erythroviruses,
such as erythrovirus genotypes 2 and 3, that may also be in-
volved in the process of chronic anemia in immunocompro-
mised patients [13–15].
Our study, which targeted both PVB19 and erythrovirus ge-
notypes 2 and 3 DNA with a real-time PCR, demonstrates that
the prevalence of erythrovirus replication was low for a large
selection of HIV-infected anemic patients, even for patients
with a low CD4 cell count. Moreover, the viral load of positive
samples was low, probably corresponding to circulating DNA
without crude active infection and without any clinical signif-
icance. The prevalence of 4% observed in our selected popu-
lation of HIV-infected patients with chronic anemia was close
to the prevalence of 1% observed in US blood donors in 2000–
2003 but seemed to be higher than the prevalence of 0.2%
observed in German and Austrian blood donors in 2004–2006
[16, 17]. It was noteworthy that, in the latter study, most of
the patients with circulating PVB19 DNA exhibited a low viral
load, !105 copies/mL [17]. This range of viral load may cor-
respond to “viral dust,” probably following a symptomatic or
not primary PVB19 old infection. Our observation supports
the hypothesis that (1) PVB19-induced anemia is an extremely
rare event for HIV-infected patients and (2) erythrovirus ge-
notypes 2 and 3 may not have any pathogenic role to play in
this population. Of note, a low CD4 cell count per se does not
seem to be sufficient to allow reactivation of PVB19 [18]. Pa-
tients who were on AZT at the time of the sampling were not
more likely to experience erythrovirus replication, compared
with patients who were on other antiretroviral drugs.
Our study has some limitations, including the cross-sectional
design and the absence of indicators of the circumstances and
characteristics of anemia (data on the reticulocyte count, the
mean corpuscular volume of red cells, and the level of serum
ferritin were not routinely collected in the Swiss HIV Cohort
Study). In conclusion, PVB19-associated anemia is a rare event
among HIV-infected patients, and erythrovirus genotypes 2 and
3 may not have any pathogenic role to play in the process of
chronic anemia in such patients. This study does not support
the extensive use of erythrovirus PCR for HIV-infected patients
with chronic anemia, except in the previously described specific
context of severe anemia with pure red cell aplasia (which was
not observed in our study).
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